Related Experiment Video
Updated: Jul 31, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[How to choose a basic drug for psoriatic arthritis?]
Orvosi Hetilap
|December 8, 1991
Summary
Methotrexate demonstrated superior efficacy in treating psoriatic arthritis (PA) across multiple parameters, showing no required withdrawals. Disease-modifying antirheumatic drugs (DMARDs) offer significant benefits for PA patients when selected and monitored appropriately.
Area of Science:
- Rheumatology
- Dermatology
- Pharmacology
Background:
- Psoriatic arthritis (PA) presents with both skin and joint manifestations.
- Optimal treatment selection for PA remains a clinical challenge.
- Disease-modifying antirheumatic drugs (DMARDs) are crucial for managing PA.
Purpose of the Study:
- To evaluate the efficacy and safety of different DMARDs in psoriatic arthritis patients.
- To compare the effectiveness of aurotherapy, sulfasalazine, etretinate, and methotrexate in PA.
- To assess the impact of DMARDs on key clinical and laboratory parameters in PA.
Main Methods:
- A prospective study involving 52 psoriatic arthritis patients treated with DMARDs (aurothiomalate, sulfasalazine, methotrexate, etretinate) for 3-6 months.
- Monitoring of morning stiffness, visual analog scale (VAS), number of swollen joints, psoriasis area and severity index (PASI), and erythrocyte sedimentation rate (ESR).
- Retrospective analysis based on earlier studies and literature data to guide initial treatment selection.
Main Results:
- Methotrexate was the most effective DMARD across most monitored parameters, with no instances of treatment withdrawal.
- Etretinate showed the second-best efficacy regarding the Psoriasis Area and Severity Index (PASI).
- Significant improvements in ESR and VAS were observed with all tested DMARDs, and low skin exacerbation rates were noted.
Conclusions:
- Methotrexate appears to be the most effective DMARD for psoriatic arthritis, particularly in severe cases.
- Appropriate selection and monitoring of psoriatic arthritis patients are essential for achieving positive outcomes with DMARDs.
- DMARDs can lead to significant clinical improvements in psoriatic arthritis, with varying efficacy and withdrawal rates among different agents.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications